The Manufacturers Life Insurance Company Takes Position in Palvella Therapeutics, Inc. $PVLA

The Manufacturers Life Insurance Company purchased a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 15,545 shares of the company’s stock, valued at approximately $2,376,000. The Manufacturers Life Insurance Company owned 0.11% of Palvella Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of PVLA. KBC Group NV bought a new position in Palvella Therapeutics in the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at $35,000. Group One Trading LLC lifted its stake in shares of Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. acquired a new position in shares of Palvella Therapeutics in the 3rd quarter valued at $36,000. Finally, Quantbot Technologies LP bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth $71,000. 40.11% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total value of $654,807.42. Following the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $327,860.34. The trade was a 66.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently commented on PVLA. HC Wainwright reiterated a “buy” rating and issued a $270.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a report on Wednesday, August 5th. Finally, Chardan Capital raised shares of Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $209.14.

Palvella Therapeutics Stock Up 1.6%

Palvella Therapeutics stock opened at $152.95 on Thursday. The company has a 50 day moving average of $147.79 and a 200-day moving average of $128.75. Palvella Therapeutics, Inc. has a twelve month low of $51.38 and a twelve month high of $161.38. The stock has a market capitalization of $2.20 billion, a PE ratio of -31.67 and a beta of -0.25.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.